文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

脑干转移瘤的分次立体定向放疗——临床结局与预后因素

Fractionated stereotactic radiotherapy of brainstem metastases - Clinical outcome and prognostic factors.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-11-21

该研究回顾性分析了65例患者共69个脑干转移瘤接受分次立体定向放疗(fSRT)的结局,处方剂量为30 Gy分6次、70%等剂量线,使用射波刀实施。中位随访27.3个月,1年总颅内脑控制率为35.0%,1年局部控制率为84.1%,中位总生存期为8.9个月。结论认为fSRT是有效且安全的治疗方式,局部控制率高、神经毒性合理,但该队列预后仍很差。

要点

  • 65例患者69个脑干转移瘤接受30 Gy分6次、70%等剂量线射波刀fSRT。
  • 1年局部控制率84.1%,1年总颅内脑控制率35.0%,中位总生存期8.9个月。
  • 局部进展发生7.7%,症状性放射性对比剂增强(RICE)8.2%,急性CTCAE 3级毒性18.4%。

核心结论

  • 作者认为fSRT是脑干转移瘤有效且安全的治疗方式,局部控制率高、神经毒性合理,但该患者队列预后仍很差。
  • 作者认为需要临床和影像随访以识别脑进展及包括RICE在内的不良毒性。

研究设计与样本

  • 回顾性分析65例患者共69个脑干转移瘤接受分次立体定向放疗(fSRT)。
  • fSRT处方剂量为30 Gy分6次、70%等剂量线,使用射波刀实施。
  • 采用Kaplan-Meier法分析总生存(OS)、局部控制(LC)和总颅内脑控制(TIBC),采用Cox比例风险模型识别预后因素。

主要发现

  • 中位随访27.3个月,1年TIBC为35.0%,1年LC为84.1%,中位OS为8.9个月。
  • 局部进展共发生7.7%,症状性放射性对比剂增强(RICE)诊断率为8.2%。
  • 急性CTCAE 3级毒性发生率为18.4%。

关键数值与推荐

  • fSRT处方剂量为30 Gy分6次,处方于70%等剂量线,使用射波刀实施。
  • 1年TIBC为35.0%,1年LC为84.1%,中位OS为8.9个月。
  • 局部进展发生率为7.7%,症状性RICE诊断率为8.2%,急性CTCAE 3级毒性发生率为18.4%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Brain metastases (BM) are the most common malignancy in the central nervous system (CNS) and observed in approximately 30% of cancer patients. Brainstem metastases (BSM) are challenging because of their location and the associated neurological risks. There are still no general therapeutic recommendations in this setting. Stereotactic radiosurgery (SRS) is one of few possible local therapy options but limited due to the tolerance dose of the brainstem. There is still no standard regarding the optimal dose und fractionation. METHODS: We retrospectively analyzed 65 patients with fractionated stereotactic radiotherapy (fSRT) for 69 BSM. FSRT was delivered at a dose of 30 Gy in six fractions prescribed to the 70 % isodose performed with Cyberknife. Overall survival (OS), local control (LC) and total intracranial brain control (TIBC) were analyzed via Kaplan-Meier method. Cox proportional hazards models were used to identify prognostic factors. RESULTS: Median follow-up was 27.3 months. One-year TIBC was 35.0 % and one-year LC was 84.1 %. Median OS was 8.9 months. In total, local progression occurred in 7.7 % and in 8.2 % symptomatic radiation-induced contrast enhancements (RICE) were diagnosed. In univariate analysis the Karnofsky performance scale index (KPI) (p = 0,001) was an independent prognostic factor for longer OS. Acute CTCAE grade 3 toxicities occurred in 18.4 %. CONCLUSION: FSRT for BSM is as an effective and safe treatment approach with high LC rates and reasonable neurological toxicity despite the poor prognosis in this patient cohort is still very poor. Clinical and imaging follow-up is necessary to identify cerebral progression and adverse toxicity including RICE.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Krämer A, Hahnemann L, Schunn F, et al. Fractionated stereotactic radiotherapy of brainstem metastases - Clinical outcome and prognostic factors. Clin Transl Radiat Oncol. 2024. PMID: 39651456. doi:10.1016/j.ctro.2024.100893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。